Our findings further extend recent literature addressing the effect of GLP-1 therapies on cancer.32 While some epidemiological studies have suggested neutral or even protective effects, our data indicate that the context, specifically concurrent treatment with immunotherapy, is critical. This evidence concerns the gene GLP1R and cancer.